Quercetin protects rat cortical neurons against traumatic brain injury

Introduction

Traumatic brain injury (TBI) is a leading cause of mortality and morbidity worldwide (1). TBI patients suffer permanent neurological and psychological disabilities that represent a significant social and economic burden. TBI-induced deficits are due to primary (mechanical impact) and secondary (delayed) injuries. It is essential to elucidate the biological cascades that drive the delayed secondary phase subsequent to TBI (2). Despite considerable progress being made in animal models and preclinical research in recent years, there are currently no available therapeutic strategies in clinical practice for TBI.

The flavonoid quercetin (3,5,7,30,40-pentahydroxyflavone), one of the most widely distributed flavonoids in fruits and vegetables, is known to be a potent anti-oxidant and free radical scavenger (3). A number of studies have demonstrated that quercetin possesses anti-inflammatory, anti-coagulation, anti-ischemic and anti-cancer activities (4–6). In addition, Yang et al (7) suggested that in TBI rats, quercetin improves cognitive function owing to its neuroprotective action via the inhibition of oxidative stress, leading to a reduced inflammatory response, thereby reducing neuronal death. It was hypothesized that post-injury treatment with quercetin may exert a therapeutic effect against TBI. Our previous study (8) provided results similar to Yang, however, the specific molecular mechanisms requires further study. The present study also analyzed the expression of Akt serine/threonine protein kinase, phosphorylated (p)-Akt, extracellular signal-regulated kinase (ERK)1/2 and p-ERK1/2 in injured neurons in the cortex, which serves an important role in signal transduction following TBI. The aim of the present study was to investigate the protective effects of quercetin on neurological impairment and spatial cognitive function after TBI in rat model. It further examined whether quercetin could attenuate neuronal apoptosis via PI3K/Akt and ERK1/2 signaling, thereby reducing brain damage.

Materials and methods

Animals

The Institutional Animal Care and Use Committee of Hebei Medical University (Shijiazhuang, China) approved all experiments, which were performed according to the guidelines of the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals (NIH Publications no. 80–23, revised 1978; NIH, Bethesda, MD, USA). All efforts were made to minimize the number of animals used and their suffering. A total of 75 male Sprague Dawley rats, weighing 280–320 g (6–8 weeks), were supplied from the Experimental Animal Center of Hebei Medical University (Shijiazhuang, Hebei, China). All animals were housed in plastic boxes at a temperature of 22–24°C, 50% humidity and were provided food and water ad libitum under a 12-h reversed light-dark cycle.

Model of TBI

The TBI model was produced using a modified weight-drop device (9). Following 10% chloral hydrate anesthesia (3 ml/kg), a midline longitudinal incision was performed to expose the skull between bregma and lambda suture lines. A steel disk (diameter, 10 mm; thickness, 3 mm) was adhered to the skull using dental acrylic. Animals were moved onto a foam mattress underneath a weight-drop device where a weight of 450 g fell freely through a vertical tube from 1.5 m onto the steel disk. Sham-operated animals underwent the same surgical procedure without weight-drop impact. Rats were placed on heat pads (37°C) for 2–4 h to maintain normal body temperature during the recovery period.

Groups and drug administration

All rats were randomly arranged into 3 groups as follows: Sham group (n=25); TBI group (n=25); and TBI + quercetin group (Que; n=25). Quercetin (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany; dissolved in 0.9% saline solution) was administered intraperitoneally at a dose of 50 mg/kg at 30 min, 12 and 24 h following the TBI insult.

In addition, 15 rats (5/group) underwent behavioral testing. All investigations were blinded and the animal groupings were revealed only at the end of the behavioral and histological analyses.

Evaluation of brain edema

Brain water content was determined at day 1, 3 and 5 following TBI (45 rats, 15/group). In order to reduce the use of animal population, at 5 days after TBI, 15 rat brains were taken from rats which had completed the behavioral experiments. Rat brains were separated and weighed immediately with a chemical balance to obtain the wet weight (WW). Following drying in a desiccating oven for 24 h at 100°C, dry tissues were weighed again to obtain the constant dry weight (DW). The percentage of water in the tissues was calculated according to the following formula: brain water (%)=[(WW-DW)/WW] ×100.

Recovery of motor function

The neurobehavioral status of the rats was evaluated at day 1, 3 and 5 after TBI using a set of 10 tasks, collectively termed the Neurological Severity Score (NSS) (10), which test reflexes, alertness, coordination and motor abilities. A point is awarded for failure to perform a particular task; therefore, a score of 10 reflects maximal impairment, whereas a healthy rat scores 0. Post-injury, NSS was evaluated at day 1, 3 and 5. Each animal was assessed by an observer who was blinded to the treatment group of the animal. The difference between the initial NSS (performed at day 1) and that at any subsequent time point was calculated for each rat, and this value (ΔNSS) reflects the spontaneous or treatment-induced recovery of motor function.

Hematoxylin and eosin (H&E) staining and neuron count

At 24 h post-TBI, 15 rats (5/group) were anesthetized as described above, and perfused intracardially with isotonic sodium chloride solution, followed by 4% (w/v) paraformaldehyde in 0.1M sodium phosphate buffer (pH=7.4). The brains were removed and fixed for 48 h in 4% (w/v) paraformaldehyde at 22–24°C. Following fixation, brains were embedded in paraffin, and sliced into 6 µm coronal sections at the level of the bregma and stained with hematoxylin (20 min) and eosin (3 sec) at 22–24°C. The staining was visualized by light microscopy at ×400 magnification (Olympus Corporation, Tokyo, Japan). The surviving and dying neurons per mm2 cortex were quantified (the nuclei of dead cells were shrunk and thickened).

Immunohistochemical

As for HE staining, the brain tissues were fixed, embedded and cut into 6 µm slices. Sections were deparaffinized with xylene and rehydrated at 60°C with graded ethanol (100, 95, 90, 80 and 70%). Endogenous peroxidase activity was blocked using 3% hydrogen peroxide for 30 min at room temperature, followed by 5% normal goat serum (AR0009; Wuhan Boster Biological Technology, Ltd., Wuhan, China) for 1 h to block non-specific protein interactions. The sections were subsequently incubated overnight at 4°C with an anti-activated caspase3 antibody (1:500; AB2302; Abcam, Cambridge, UK). Following three washes with PBS, the slides were incubated with a biotinylated goat anti-mouse horseradish peroxidase conjugated secondary antibody (1:100, BA1051; Wuhan Boster Biological Technology Ltd.) for 2 h at room temperature. The sections were washed with PBS again, and incubated with the kit-provided horseradish peroxidase (HRP)-streptavidin for 30 min at room temperature. The peroxidase reaction was visualized using 0.05% diaminobenzidine + 0.01% hydrogen peroxide. Immunohistochemical procedures were performed in accordance with the manufacturer's protocols. The positive cells were visualized by a microscope at ×100 magnification.

Western blotting

The rats were deeply anesthetized as described above 24 h following TBI. The cortical region of the rat brain was rapidly isolated. The segments were immediately stored at −80°C for further analysis. Total protein samples were extracted from brain tissues using whole cell lysis buffer (WD2072; Beyotime Institute of Biotechnology, Shanghai, China) a bicinchoninic acid protein assay kit (P10310; Beyotime Institute of Biotechnology) was used to determine the protein concentration of each sample. The homogenate was heated to 100°C for 10 min and centrifuged again at 15,294 × g for 1 min at 22–24°C. Equal amounts (80 µg) of protein were subjected to Tris-HCl SDS-PAGE on 8 and 12% gels (Bio-Rad Laboratories, Inc., Hercules, CA, USA) for 30 min at 70 V and 60 min at 120 V. Following electrophoresis, the proteins were transferred onto polyvinylidene fluoride membranes (EMD Millipore, Billerica, MA, USA) at 300 mA for immunoblotting. Following blocking with 5% skimmed milk for 2 h at room temperature, membranes were incubated overnight at 4°C with the following primary antibodies: Rabbit anti-activated Caspase3 (AB2302; 1:1,000; Abcam), rabbit anti-Akt (AB81283; 1:1,000; Abcam), rabbit anti-p-Akt (AB38449; 1:1,000; Abcam), rabbit anti-ERK1/2 (AB17942; 1:1,000; Abcam), rabbit anti-p-ERK1/2 (AB214362; 1:1,000; Abcam), and rabbit anti-β-actin (AB227387; 1:5,000; Abcam). Following three washes in TBS-Tween 20, membranes were incubated with a horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G (BL003A; 1:5,000; EMD Millipore) for 2 h at room temperature. Protein bands were visualized using an enhanced chemiluminescence kit (Beyotime Institute of Biotechnology). Band density was quantified via detection with a DNR Micro Chemi chemiluminescence gel imaging system (DNR Bio-Imaging Systems Ltd., Neve Yamin, Israel). Each band density was normalized to the density of β-actin.

Statistical analysis

SPSS software version 16.0 (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis. A statistical evaluation of the data was performed using a one-way analysis of variance, followed by post hoc comparisons using the least significant difference or Kruskal-Wallis method. All experimental data are expressed as the mean ± standard error of the mean, and P<0.05 was considered to indicate a statistically significant difference.

Results

Quercetin attenuates TBI-induced cerebral edema

Following injury, brain edema leads to an elevation in intracranial pressure, reducing cerebral perfusion pressure and brain oxygenation. Edema is associated with the resultant pathology following TBI (11). In order to evaluate the effects of quercetin on brain edema, the wet-dry weight method was used in the present study to evaluate brain edema at day 1, 3 and 5 after TBI. As presented in Fig. 1, cerebral water content was significantly increased at day 1, 3 and 5 after TBI compared with the sham group (P<0.01). However, treatment with quercetin attenuated this increased compared with the TBI model group (P<0.05).

Figure 1. Effect of treatment with quercetin on brain edema. Brain water content was determined at day 1, 3 and 5 following TBI. Bars represent mean ± standard error of the mean (n=5/group). Cerebral water content was significantly increased at day 1, 3 and 5 following TBI (##P<0.01 vs. sham group). However, treatment with quercetin attenuated this increase compared with the TBI model group (*P<0.05 vs. TBI group). TBI, traumatic brain injury; Que, quercetin-treated.

Quercetin attenuates TBI-induced motor deficits

Motor deficit recovery was expressed as ΔNSS in present study. Alterations in the functional recovery of rats at day 1, 3 and 5 are depicted in Fig. 2. It was observed that rats exhibited marked motor deficits following TBI. Post-injury administration of quercetin significantly improved the motor function between day 1 and 5 after trauma compared with the TBI group (P<0.05).

Figure 2. Effect of treatment with quercetin on TBI-induced motor deficits. The temporal alterations in motor recovery were determined at day 1, 3 and 5 following TBI and calculated as ΔNSS. Bars represent mean ± standard error of the mean (n=5/group). Rats exhibited significant motor deficits post-TBI. Post-injury administration of quercetin significantly improved the motor function at day 1, 3 and 5 following injury (*P<0.05 vs. TBI group). TBI, traumatic brain injury; NSS, Neurological Severity Score; Que, quercetin-treated.

Quercetin increases neuronal survival in the cortical region of brain

Cortical regions of brains were collected and neuronal survival was assessed at 24 h via H&E staining. As presented in Fig. 3, the nuclei of normal neurons were round and stained pale, whereas nuclei of dying neurons were pyknotic and darkly stained following TBI. The survival rate of neurons in the quercetin-treated group was significantly improved compared with that of the TBI group (P<0.05).

Figure 3. Effect of quercetin on the survival rates of neurons in the cortical region at 24 h. Representative hematoxylin and eosin staining of neurons from the Sham, TBI and Que groups. Bars represent the percentages of surviving neurons as the mean ± standard error of the mean (n=5/group). ##P<0.01 vs. sham group; *P<0.05 vs. TBI group. Scale bar, 50 µm. TBI, traumatic brain injury; Que, quercetin-treated.

Quercetin attenuates neuronal apoptosis in the cortex

In order to assess the effect of quercetin on neuronal apoptosis following TBI, immunohistochemical and western blot analyses were used to assess alterations in caspase3 expression, respectively. As depicted in Fig. 4A, representative photomicrographs exhibited a high density of caspase3-positive cells in the TBI group compared with the sham group at 24 h. However, the expression of activated caspase3-positive cells notably decreased in the quercetin treatment group. In addition, western blot analysis revealed that, compared with the sham group, the protein expression levels of activated caspase3 increased significantly in the TBI group at 24 h (P<0.01), and the levels of caspase3 exhibited a significant downregulation at the same time point following treatment with quercetin (P<0.05; Fig. 4B and C).

Figure 4. Effect of quercetin on Caspase3 expression following TBI. (A) Representative images of immunohistochemical analysis of Caspase3 in the sham, TBI and Que groups at 24 h. Scale bar, 100 µm. (B) Western blot analysis demonstrating expression levels of caspase3 in the cortex of rats at 24 h. (C) The quantitative results of caspase3 are expressed as the ratio of densitometries of caspase3 to β-actin bands. Bars represent the mean ± standard error of the mean (n=5/group). The results demonstrated that the protein levels of caspase3 increased significantly in the TBI group at 24 h (##P<0.01 vs. sham group), and the levels of caspase3 exhibited significant downregulation at following treatment with quercetin (*P<0.05 vs. TBI group). TBI, traumatic brain injury; Que, quercetin-treated.

Quercetin induces the activation of the Akt signaling pathway in the cortex following TBI

Western blot analysis was performed to investigate the expression of Akt and p-Akt at 24 h after TBI in the 3 groups. As presented in Fig. 5, the level of p-Akt was increased following TBI compared with that in the sham group (P<0.05). Additionally, administration of quercetin produced a significant elevation of p-Akt (P<0.01). No significant difference in total Akt protein expression was observed among the 3 groups.

Figure 5. Effect of quercetin on the Akt pathway. Western blot analysis demonstrated the expression levels of Akt and p-Akt in the Sham, TBI and Que groups at 24 h. The quantitative results of Akt and p-Akt are calculated as the ratio of the densitometries to β-actin bands, and expressed as the mean ± standard error (n=5/group). #P<0.05 vs. sham group; **P<0.01 vs. TBI group. TBI, traumatic brain injury; Que, quercetin-treated; Akt, Akt serine/threonine protein kinase; p, phosphorylated.

Quercetin attenuates the ERK1/2 signaling pathway following TBI

Western blot analysis was performed to investigate the expression of ERK1/2 and p-ERK1/2 at 24 h after TBI in the 3 groups. As presented in Fig. 6, the level of p-ERK1/2 was increased significantly post-TBI, compared with the sham group (P<0.01). However, the administration of quercetin produced a significant attenuation of p-ERK1/2 levels compared with the TBI group (P<0.01). No significant difference in total ERK1/2 protein expression was observed among the 3 groups.

Figure 6. Effect of quercetin on the ERK1/2 signaling pathway. Western blot analysis demonstrated the expression levels of ERK1/2 and p-ERK1/2 in the sham, TBI and Que groups at 24 h. The quantitative results of ERK1/2 and p-ERK1/2 are calculated as the ratio of the densitometries to β-actin bands, and expressed as the mean ± standard error (n=5/group). ##P<0.01 vs. sham group; **P<0.01 vs. TBI group. TBI, traumatic brain injury; Que, quercetin-treated; ERK, extracellular signal-regulated kinase; p, phosphorylated.

Discussion

The aim of the present study was to investigate the neuroprotective effects of quercetin on TBI. H&E staining is a macroscopic and readily available method to assess histopathological changes. Quercetin treatment notably attenuated injury. In the Que group, the structure of the brain tissue was improved and the number of neurons increased compared with the TBI group. In addition, TBI-induced neurological deficits and brain edema was suppressed by treatment with quercetin. At the molecular level, treatment with quercetin significantly inhibited the TBI-induced expression of cleaved Caspase3. It was additionally observed that the neuroprotective effects of the drug were associated with activation of the Akt signaling pathway, and inhibition of the ERK signaling pathway. The results of the present study were consistent with previous studies demonstrating that quercetin may exert neuroprotection in various in vitro and in vivo models (12–15). Therefore, it is hypothesized that quercetin may have the potential to become a novel therapeutic for TBI.

The primary injury occurs at the moment of TBI impact, with disruption of the blood brain barrier and blood vessels that contribute to immediate (necrotic) cell death (16). Subsequently, oxygen free radical-mediated lipid peroxidation, inflammation and brain edema appear to be fundamental mechanisms underlying secondary damage in TBI (17). In the present study, caspase3 was induced by TBI, which is a key executor in the process of apoptosis in neurons (18). However, treatment with quercetin significantly inhibited the TBI-induced expression of cleaved caspase3. These observations were consistent with a previous study, which demonstrated that caspase3 immunoreactivity was reduced by quercetin in the cerebral ischemic penumbra in rats (19). The neuroprotective effect of quercetin was associated with the inhibition of neuronal apoptosis.

Akt, also termed protein kinase B, is a serine/threonine kinase with pro-survival functions in acute brain injury (20). Extracellular signals frequently result in the simultaneous activation of the PI3K/Akt signaling pathway, and a number of reports have suggested a survival role of the PI3K/Akt signaling pathway through the suppression of apoptosis (21,22). Additionally, previous studies have demonstrated that the intrinsic pathway is characterized by mitochondrial outer membrane permeabilization, death-inducible signaling complex formation, DNA fragmentation and caspase3 activation. These events have been demonstrated to be associated with ERK1/2 signaling pathway activation (23,24). In the present study, treatment with quercetin inhibited the TBI-induced activation of the ERK1/2 signaling pathway, and further enhanced the PI3K/Akt pathway in TBI-injured neurons. Therefore, the neuroprotective effects of quercetin may be associated with ERK1/2 inhibition in addition to PI3K/Akt activation.

Previous studies have showed that in TBI rats, quercetin improves cognitive function due to its neuroprotective action via the inhibition of oxidative stress, leading to a reduced inflammatory response and thereby reducing neuronal death (7,8). Compared with other studies, the present study performed a more in-depth study on the molecular mechanism of the neuroprotection effects of quercetin. It was demonstrated that post-TBI administration of quercetin may attenuate brain edema and improve motor functions in rats. In addition, quercetin caused marked ERK1/2 inhibition and PI3K/Akt activation, and thereby attenuation of neuronal apoptosis. The present study provides novel insight into the mechanisms through which quercetin may exert its neuroprotective activity in a rat model of TBI.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

All datasets on which the conclusions are based are provided in the present article.

Authors' contributions

GD, ZZ and YC designed the present study. ZoL, YT and ZhL performed the experiments. BL and JS analyzed and interpreted data, and were major contributors in writing the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The Institutional Animal Care and Use Committee of Hebei Medical University (Shijiazhuang, China) approved all experiments, which were performed according to the guidelines of the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals (NIH Publications no. 80–23, revised 1978; NIH, Bethesda, MD, USA). All efforts were made to minimize the number of animals used and their suffering.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Glossary

Abbreviations

Abbreviations:

References